AR062419A1 - Terapia tumoral con un anticuerpo anti- vegf - Google Patents

Terapia tumoral con un anticuerpo anti- vegf

Info

Publication number
AR062419A1
AR062419A1 ARP070103667A ARP070103667A AR062419A1 AR 062419 A1 AR062419 A1 AR 062419A1 AR P070103667 A ARP070103667 A AR P070103667A AR P070103667 A ARP070103667 A AR P070103667A AR 062419 A1 AR062419 A1 AR 062419A1
Authority
AR
Argentina
Prior art keywords
vegf antibody
tumor therapy
treatment
antibody
her2
Prior art date
Application number
ARP070103667A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR062419A1 publication Critical patent/AR062419A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Un método para el tratamiento de un paciente que padece una recaída de cáncer HER2 positivo con un anticuerpo anti-VEGF durante o después de un tratamiento con un anticuerpo anti-HER2. Los correspondientes artículos para su elaboracion.
ARP070103667A 2006-08-21 2007-08-17 Terapia tumoral con un anticuerpo anti- vegf AR062419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21

Publications (1)

Publication Number Publication Date
AR062419A1 true AR062419A1 (es) 2008-11-05

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103667A AR062419A1 (es) 2006-08-21 2007-08-17 Terapia tumoral con un anticuerpo anti- vegf

Country Status (29)

Country Link
US (6) US20080050385A1 (es)
EP (2) EP2056874B1 (es)
JP (3) JP2010501498A (es)
KR (1) KR101136763B1 (es)
CN (1) CN101505792B (es)
AR (1) AR062419A1 (es)
AU (1) AU2007287794B2 (es)
BR (1) BRPI0715829A2 (es)
CA (1) CA2660681A1 (es)
CL (1) CL2007002404A1 (es)
CO (1) CO6150193A2 (es)
CR (1) CR10590A (es)
DK (1) DK2056874T3 (es)
ES (2) ES2546066T3 (es)
HK (1) HK1134441A1 (es)
IL (2) IL196810A0 (es)
MA (1) MA30654B1 (es)
MX (1) MX2009001715A (es)
MY (1) MY150756A (es)
NO (1) NO20090450L (es)
NZ (1) NZ574580A (es)
PE (1) PE20080911A1 (es)
PL (1) PL2056874T3 (es)
RU (1) RU2528884C2 (es)
SG (1) SG174090A1 (es)
SI (1) SI2056874T1 (es)
TW (2) TW201107346A (es)
WO (1) WO2008022746A1 (es)
ZA (1) ZA200901200B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101711868A (zh) 2000-05-19 2010-05-26 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
SI1771482T1 (sl) 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
US7449184B2 (en) * 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20080050385A1 (en) 2006-08-21 2008-02-28 Thomas Friess Tumor therapy with an anti-vegf antibody
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
BR112012033423A2 (pt) * 2010-07-19 2016-10-25 Hoffmann La Roche métodos para melhorar a eficácia do tratamento de um regime de quimioterapia e in vitro, usos de bevacizumab e de sondas específicas, kit e uso de um polipeptídeo
MX2013002046A (es) * 2010-08-20 2013-04-03 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
SI2766040T1 (sl) 2011-10-14 2019-08-30 F. Hoffmann-La Roche Ag Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
SG11201402737SA (en) * 2011-12-05 2014-06-27 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US20150147340A1 (en) * 2012-03-30 2015-05-28 Fibrogen, Inc. Therapeutic methods for peritoneal carcinomatosis
CA3071678A1 (en) 2013-04-16 2014-10-23 Genentech,Inc. Pertuzumab variants and evaluation thereof
CA2946860A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
MA56006A (fr) 2017-01-17 2022-05-04 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
EP4208167A1 (en) * 2020-09-04 2023-07-12 The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Combination compositions and methods for treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
BRPI9809388B8 (pt) 1997-04-07 2021-05-25 Genentech Inc anticorpos humanizados e métodos para a formação de anticorpos humanizados.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
IL139707A0 (en) 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CZ2001660A3 (cs) 1998-08-27 2002-05-15 Pfizer Products Inc. Alkynylsubstituované chinolin-2-ony, farmaceutické kompozice a způsoby léčení na jejich bázi a způsob výroby těchto sloučenin
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
AU2124800A (en) 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
ES2282120T3 (es) 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP4488740B2 (ja) * 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2005012531A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JP4937127B2 (ja) * 2004-10-04 2012-05-23 ジェネンテック， インコーポレイテッド 肝細胞成長因子活性化物質のモジュレータ
BRPI0611766A2 (pt) * 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20080050385A1 (en) 2006-08-21 2008-02-28 Thomas Friess Tumor therapy with an anti-vegf antibody
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
MX2009001715A (es) 2009-02-25
TW200825106A (en) 2008-06-16
SG174090A1 (en) 2011-09-29
CO6150193A2 (es) 2010-04-20
BRPI0715829A2 (pt) 2013-07-23
US20100285010A1 (en) 2010-11-11
IL196810A0 (en) 2011-08-01
NO20090450L (no) 2009-02-27
TW201107346A (en) 2011-03-01
IL238045A0 (en) 2015-05-31
US20080050385A1 (en) 2008-02-28
CN101505792A (zh) 2009-08-12
HK1134441A1 (en) 2010-04-30
US20110223159A1 (en) 2011-09-15
CA2660681A1 (en) 2008-02-28
MY150756A (en) 2014-02-28
JP2010501498A (ja) 2010-01-21
MA30654B1 (fr) 2009-08-03
DK2056874T3 (da) 2012-10-15
US20130183292A1 (en) 2013-07-18
NZ574580A (en) 2011-12-22
SI2056874T1 (sl) 2012-12-31
JP2013163687A (ja) 2013-08-22
US20180251536A1 (en) 2018-09-06
EP2056874B1 (en) 2012-09-19
WO2008022746A1 (en) 2008-02-28
RU2009110102A (ru) 2010-09-27
CR10590A (es) 2009-03-20
CN101505792B (zh) 2012-10-03
ES2392630T3 (es) 2012-12-12
PE20080911A1 (es) 2008-08-15
CL2007002404A1 (es) 2008-04-18
PL2056874T3 (pl) 2013-02-28
KR101136763B1 (ko) 2012-04-24
EP2441472B1 (en) 2015-06-10
EP2056874A1 (en) 2009-05-13
EP2441472A1 (en) 2012-04-18
AU2007287794A1 (en) 2008-02-28
ZA200901200B (en) 2013-08-28
RU2528884C2 (ru) 2014-09-20
KR20090032136A (ko) 2009-03-31
ES2546066T3 (es) 2015-09-18
US20150239969A1 (en) 2015-08-27
JP2015214582A (ja) 2015-12-03
AU2007287794B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
AR062419A1 (es) Terapia tumoral con un anticuerpo anti- vegf
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CY1121813T1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PA8637101A1 (es) Terapia para el cancer resistente al platino
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
HK1143190A1 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
NO20082683L (no) Neuroendokrin tumorbehandling
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
SG11202112800SA (en) Illumination for photodynamic therapy
EA201492104A1 (ru) Ингибитор jak1/2
CY1124688T1 (el) Θεραπεια πρωτεϊνουριας
WO2008054598A3 (en) Panel of biomarkers for prediction of fti efficacy
NO20093536L (no) Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab
CL2012000387A1 (es) Método para tratar a un paciente diagnosticado con cáncer de mama previamente tratado metastásico que comprende la combinación de una quimioterapia con la administración de un anticuerpo anti-vegf; y kit utilizado.
TR201908138T4 (tr) Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.

Legal Events

Date Code Title Description
FB Suspension of granting procedure